

Center for Medicaid, CHIP, and Survey & Certification

November 1, 2010

MEDICAID DRUG REBATE PROGRAM

Release No. 82



For
Participating Drug Manufacturers



INCORRECT DRUG PRODUCT INFORMATION REPORTED TO CMS

Unit Type and Units Per Package Size

In accordance with section 1927 of the Social Security Act, labelers are required to submit and certify valid drug product data for a national drug code (NDC) before establishing and submitting quarterly pricing data. Drug product data includes both 9-digit and 11-digit NDC data fields.

Labelers are also responsible for submitting corrections to drug product data via the Drug Data Reporting for Medicaid (DDR) system. In an effort to make our reporting fields consistent and ensure uniformity in our drug product file, we request manufacturers to review their NDC's drug product data to ensure that one of the following eight unit types are used when submitting or updating product information:

For this Dosage	Apply This Unit Type	Abbreviation
Anti-Hemophilic Factor Injectables	Injectable Anti-Hemophilic Factor	AHF
All drugs dispensed in capsule form	Capsule	CAP
Drugs not identifiable by another unit; e.g., powder-filled vials, powder-filled ampules, powder-filled packets, and kits containing two or more items dispensed under one NDC and sold at a single price	Each	EA
Drugs measured by weight; e.g., creams, ointments, foams, powders, gels	Gram	GM
Drugs measured by liquid volume, e.g., oral or topical solutions, suspensions, lotions, sprays, liquid-	Milliliter	ML

filled vials, liquid-filled ampules, pre-filled syringes, all liquid ophthalmic products		
All suppositories whether dispensed individually or in dosage packets	Suppository	SUP
All drugs dispensed in tablet form	Tablet	TAB
All drugs dispensed as Transdermal Patches	Transdermal Patch	TDP

Further, we request that labelers review their drug product data to ensure that the Units per Package Size (UPPS), currently defined as the total number of units in the smallest dispensable amount for the 11-digit NDC, is submitted accurately. This is in accordance with our instruction on how to report for the UPPS field in our Drug Product Data Web File Structure and Definition on our website at <http://medicaid.gov/Medicaid-CHIP-Program-Information/By-Topics/Benefits/Prescription-Drugs/Downloads/RecordSpecificationandDefinitions.pdf>. Below is additional information on how to report the UPPS.

- When the pharmacist routinely dispenses the drug as it is packaged (an unbreakable quantity), you should show the UPPS as the actual size of the container.

Example: The unit type is a tablet, the NDC is for a package size holding 20 tablets, and the pharmacist is expected to dispense the entire container, rather than dispensing a smaller number of tablets from it. The appropriate entry in the UPPS field is "20."

- Where the number of units in the package size is such that the pharmacist is not expected to routinely dispense the entire package to the retail customer, (a breakable quantity), the appropriate entry in the UPPS field is "1".

Example: The unit type is a tablet, the package holds 500 tablets and the usual quantity prescribed by the doctor and dispensed by the pharmacist is fewer than 500 tablets. The UPPS entry should be "1".

In the future, we plan to post a file containing drug product data, without pricing data, at the 11-digit NDC level for labeler review on our website. We will be providing notification of such postings via our Medicaid Prescription Drug Policy & Reimbursement Updates mailing list. If you do not currently subscribe to this mailing list, please click on the following link to activate your subscription - https://subscriptions.cms.hhs.gov/service/subscribe.html?code=USCMS_589.

Drug Category and FDA Approval Date

In Manufacturer Release #80, we requested manufacturers to check the FDA website to ensure that the correct drug category is submitted to CMS. We are again requesting manufacturers to review the drug category of their reported products to ensure the accuracy of the data submitted to the CMS.

In general, those products that are approved under a New Drug Application (NDA) need to be reported to CMS as either single source (S) or innovator multiple source (I), and those products approved under an Abbreviated New Drug Application (ANDA) need to be reported to CMS as non-innovator multiple source (N).

We continue to encourage manufacturers to check the Food and Drug Administration's (FDA) NDC Directory, <http://www.accessdata.fda.gov/scripts/cder/ndc/default.cfm>, to determine whether

the correct application number has been reported to the FDA for the product or to identify the correct drug category for the product based on the application number assigned to the product.

The FDA has also updated their Orange Book to reflect the FDA approval date by each specific product. Therefore, manufacturers may access the FDA's Orange Book, <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, and search by Application Number to determine whether a product has been approved under an NDA (marked by an "N" in front of the application number) or ANDA (marked by an "A" in front of the application number), and whether the FDA approval date reported to CMS is the same date as listed in the Orange Book.

Furthermore, we have noticed that there has been some confusion as to when a brand name product should be reported as an "I" and when it should be reported as an "S." We want to ensure that manufacturers are reporting the correct drug category for a brand name product. An "I" should be reported to CMS for a brand name drug that has a generic drug available. To know if a brand name drug has a generic drug available or not, you can access Drugs@FDA at http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Addlsearch_d rug_name and search by the Application Number. If a generic drug is available, you will see the link to "Therapeutic Equivalents" in the middle of the "Drugs Details" page. Click on this link to see the generic and other therapeutically equivalent drug products. If there is no generic drug available for a brand name drug, then the brand name drug should be reported as an "S" to CMS.

If you determine that an incorrect drug category has been reported to CMS for a product, please e-mail RxDrugPolicy@cms.hhs.gov to request a drug category change for the product. Please note that changing the drug category from "S" to "I" does not require CMS prior approval; therefore, please access the DDR to do so.

Also, please note that under section 510 of the Federal Food, Drug and Cosmetic Act, as amended, with some limited exceptions, firms that manufacture, prepare, propagate, compound, or process drugs in the United States or that are offered for import into the United States are required to be registered with the FDA. *See* 21 U.S.C. §§ 360(b), (c), (d), and (i). Every person who registers must, at the time of initial registration, list all drugs manufactured, prepared, propagated, compounded, or processed for commercial distribution. 21 U.S.C. § 360(j)(1). *See also* 21 C.F.R. 207.20. Registering and listing updates must include drugs not previously listed (if any), and certain changes to information for previously listed drugs. 21 U.S.C. § 360(j)(2); 21 CFR 207.21(b), 207.30. Prescription drug products that are properly listed should appear in the FDA's NDC Directory.

If you determine that your product is not currently listed or has been incorrectly listed with the FDA, please contact the FDA at eDRLS@fda.hhs.gov to update your product listing.

Penalties for Failure to Provide Timely Information and False Information

We would like to remind manufacturers that section 1927(b)(3)(C)(ii) states "any manufacturer with an agreement under this section that knowingly provides false information is subject to a civil money penalty in an amount not to exceed \$100,000 for each item of false information." Therefore, we encourage manufacturers to carefully review their drug product data submissions, determine if any necessary change is needed, and take the necessary steps to make the change.

We ask that the labelers review and update their drug product data, and submit any correction or a change request, when necessary, in accordance with the guidance provided in this release.

Questions regarding Medicaid drug provisions can be submitted through the drug policy resource mailbox at RxDrugPolicy@cms.hhs.gov.

UPCOMING FILE FORMAT CHANGE TO COLLECT MONTHLY AMP UNITS

In accordance with section 1927 of the Social Security Act, as amended by the Affordable Care Act, manufacturers are required to report the total number of units that are used to calculate the monthly average manufacturer price (AMP) for each covered outpatient drug no later than 30 days after the last day of the month. Manufacturers are to report these units by the same unit type they use to calculate the monthly AMP.

We plan to require manufacturers to report the AMP units to CMS via the Medicaid Drug Data Reporting (DDR) system for the October 2010 reporting period. The new data field will be called "AMP Units". The AMP units should include the total sum of units for all package sizes included in the calculation of the AMP, and should be reported per product code (9-digit NDC level) for the monthly reporting period covered. For system implementation purposes, the data field will be: Numeric values, 14-digit field: 11 whole numbers, the decimal place (".") and two (2) decimal places; right-justified; zero-filled.

Once approval from the Office of Management and Budget is obtained, manufacturers will be notified via the Medicaid Prescription Drug Policy & Reimbursement Updates mailing list as to when the AMP unit field is available to report in the DDR system. If you do not currently subscribe to the Medicaid Prescription Drug Policy & Reimbursement Updates mailing list, please click on the following link to activate your subscription:

https://subscriptions.cms.hhs.gov/service/subscribe.html?code=USCMS_589

Questions regarding Medicaid drug provisions can be submitted to the drug policy resource mailbox at RxDrugPolicy@cms.hhs.gov.

Suzanne Bosstick /s/ for

Barbara Edwards
Director
Disabled and Elderly Health Programs Group

Attachment:

cc:
Regional Administrators

CMS RECORD SPECIFICATION
DDR MONTHLY PRICING DATA
TEXT FILE FOR TRANSFER TO CMS

Source: Drug Manufacturers
Target: CMS

Field	Size	Position	Remarks
Record ID	1	1 - 1	Constant of "M"
Labeler Code	5	2 - 6	NDC #1
Product Code	4	7 - 10	NDC #2
Package Size	2	11 - 12	NDC #3
Month	2	13 - 14	MM
Year	4	15 - 18	YYYY
Average Mfr Price (AMP)	12	19 - 30	99999.999999
AMP Units	14	31 - 44	99999999999.99
Filler	21	45 - 51	spaces

TOPICAL INDEX – DRUG MANUFACTURER RELEASES 1 - 82

TOPIC	RELEASE #
340B Program	46, 51
50% Rebate Cap - Technical Amendment Passed	07
400/400 Edit Reports	75
Active Pharmaceutical Ingredient & Excipient Removal	81
Affordable Care Act (ACA)	81
Adding New Package Sizes to Existing Products	09
Additional Rebate Calculation Revision	10
Address Change (Express Mail)	70
Adjustment Code for CMS-304 & CMS-304a	21, 77
Adjustments that Cause Rebate Corrections	26
Administrative Fees' Effect on AMP & BP	14
Anthrax/Delay of 3/2001 Data	53
Average Manufacturer Price (AMP):	
BP/UPPS Clarification	03
Additional Guidance - AMP calculation	29, 31
Calculation Methodology Revision	14, 61, 78, 80
For Terminated Drugs	07
Hemophilic Drugs Clarification	11
Monthly AMP Methodology (Assumptions)	78
Monthly AMP Units & File Record Layout	82
Multiple Package Size	43
Reporting Zero or Negative AMP	80
AMP/BP	
Calculating for Different Quarters	07
Calculations-Pharmacy Benefit Managers (PBMs)	28-29
Recalculations	78, 80
Backup Drug Rebate Library	73
Baseline Change Resulting from OBRA of 1993	13, 15
Batch Edit Report Summary Sheet E-mailed	65
Best Price (BP):	
340B Covered Entities	51
Calculation Methodology Revision	78, 80
Calculation (VHCA)	06
DSH Covered Entities	11
Effect of Sales to HMOs, etc.	47, 68
Exclusions	07
MPDIMA of 2003	63
TennCare	11, 38
Versus Average Manufacturers Price	15
Buying Innovator Products for Resale	26, 38
Closure During Federal Furloughs	21
Common Data Errors	02
Contact Information/Ownership Changes	04, 06, 17, 21, 33, 63
CPI-U Rounding	78, 79
CPI-U Values	22, 48
Data Definition Update	04, 10
Data Edit Reports:	
Batch Edit Reports/Maintaining Backup Files	73
Revised Cover Letters	73

TOPICAL INDEX – DRUG MANUFACTURER RELEASES 1 - 82

TOPIC	RELEASE #
Data File Update	02
Data Requests	59
Deficit Reduction Act of 2005 (DRA)	76
Depot Prices	03
Depot Prices-TRRx	69
DESI:	
Codes	09
Field Changes	15
Indicator Change	03-04
Program Overview	04
Discounts/Price Arrangements	02
Diskette Program/Data File (New)	5, 53
Diskette Users	07, 33, 38, 53
WINDOWS Version Only	25, 27
Dispute Resolution Issues	24, 26, 31, 39
E-Mail Address/Contacts	62, 81
Meetings	65, 67, 70, 72, 77, 79
Transfer of Function	58
Web Site	59
Workgroup Survey Results	13
Drug Category Change /Reporting	23, 80
Drug Data Reporting for Medicaid (DDR)	76
Package Size Intro Date	78
Purchase Product Date	78
Drug Product Deletions/Reporting Requirements	04, 30, 45
Drug Product Information Changes	03, 30, 45
Duplicate Payment Prevention (VHCA)	06
E-Mail Address for Operational Questions	72
E-Mail Address for Technical Questions	60
Failure of Manufacturers to Notify States of	
Disputes or Pay Rebates	24
Failure to Submit Pricing Timely	81
FDA:	
Approval Date	09, 73
FDA Date Submission for OTC Drugs	10
FR Notices	80
FDA/MDRI Data Match	51, 52, 54, 55
New Drug Determinations	80
Hands-On Training	22, 23
Heparin/Saline Flush Syringes & Other Non-Drug Products	66
HIPAA – Prescription Numbers	59
Hotline	11, 18
Improper Rebate Withholding/Interest Implications	54
Individual Co-Payments or Insurance Payments	06
Information Sharing	21
Inner/Outer NDC Numbers (reporting)	71
Interest Calculation under Section V(b)	07, 40, 46
Interest:	

TOPICAL INDEX – DRUG MANUFACTURER RELEASES 1 - 82

TOPIC	RELEASE #
Failure to Pay	26, 40
When PPAs are Submitted	58
Internet:	
Home Page	38, 50, 56, 72
Prescription Reimbursement Information	59
Pharmacy Plus Demonstrations	59
Invoices:	
CMS R-144 (State Invoice) – Changes	75, 79
Invoice/Remittance Advice Report Survey	10
Invoicing for State Pharmacy Assistance Programs	57
Postmark Date for Web Invoices	80
Labeler Codes - Addition Procedures	13
Late Data Submissions	04, 09, 53
Mailing Pricing Data\Other Correspondence to CMS	06, 17, 21, 36
Market Date	09, 73
MDR Technical E-mail Address	60, 69
Medicaid Drug Rebate Data Guide for Labelers	78
Minimum Rebate Percentage & Rebate Cap (VHCA)	06, 07
Multiple Package Sizes	57
New Diskette Program/Data File	05
New Package Size Reporting	51
OIG Review	57
Omnibus Budget Reconciliation Act of 1993	09
Parenteral/Enteral Products	02
Partial Rebate Payments	19
Personnel Changes	60, 65, 71
Pharmacy Benefit Managers (PBMs)	28, 30
Pharmacy Plus Demonstrations Webpage	59
Policy E-Mail Address	53, 56
Powder-Filled Vials, Ampules, & Syringes	11
Prescription Reimbursement Information Website	59
Prior Authorization	19
Prior Period Adjustment Processing	19
Prior Quarter Adjustment Statement (PQAS) Approval	22
Prior Quarter Adjustment Statement Form Use	27, 32, 62
Proposed Discount Equal Access Legislation	16
Public Health Service Drug Pricing Program	13
Publication of Drug Rebate Regulations CMS-2175-FC	61
Quarterly Pricing Data:	
Notification of Receipt	63
Requirements	02-03, 07, 08, 12, 38
Revisions/Updates (diskette and telecommunication)	69
Questions and Answers	26
Rebate Agreement: Optional Effective Dates	46
Rebate Percentages for 1994	12
Rebates for Drugs Purchased Through the FSS	53
Rebates on OTC Drug Product	06
Rebate/Reimbursement Issues	25, 31, 54

TOPICAL INDEX – DRUG MANUFACTURER RELEASES 1 - 82

TOPIC	RELEASE #
Recalculation Requests	76, 78
Reconciliation of State Invoice (ROSI) Approval	22, 26
Reconciliation of State Invoice Form Use	27, 32, 62
Recordkeeping Regulations	63
Regulation (CMS-2175-F)	67
Regulation (CMS-2238-P)	76
Regulations, Publication of Proposed	19
Re-Introducing a Product to the Market	73
Remittance Advice Report (RAR)	07, 15-16, 20
Remittance Advice Report Implementation Workgroup	17-18
Reporting NDCs for Generic Products	04
Re-Use of NDCs	51, 73
Selling Products to Another Labeler	43, 48
Separate Rebate Agreements with States	11, 48, 53
Shelf Life	03, 31
Staff Relocation	16, 35, 36, 37
State Issues:	
Hearing Process	13
Rebate Payments	03
Remittance Advice Contacts	09
State Pharmacy Assistance Programs (SPAP)	
Best Price List	80
Revised Criteria	59, 68, 73
State/R.O. Drug Rebate Contact Persons	06, 08, 17, 46
T-bill Rates	37, 39, 65, 80
Technical Contacts	62
Tennessee Behavioral Health Pharmacy Benefit	38
Termination Appeal Process	11
Termination Dates	31, 48, 79
Termination From Program	19
Therapeutic Equivalency Code	25-26
Tolerance Threshold for Interest	15
Training Guide Obsolete	77
Unique Medicaid Factors & Rebate Disputes	14
Unit-Dose Packaging	04
Unit Rebate Amount Discrepancy Report	37
Unit Rebate Calculation (URA)	02, 78
New CMS Edits	13
Recalculations	24, 38
Recalculations for Incorrect URAs for 1Q98	35, 36
Rounding Method Change	46, 47, 48, 51, 78
Discrepancy Report	34
Unit Type:	
Convert to NCPDP 7 plus add AEACH@(EA)	13
Conversion Date Change	09
EACH	73
Reporting	82
Specification Changes	06, 08

TOPICAL INDEX – DRUG MANUFACTURER RELEASES 1 - 82

TOPIC	RELEASE #
Units Per Package Size	82
Updated Version of Diskette Program/Sterling Reporting	67
Utilization Adjustments	22
VA Appropriations Act	03
Vermont Rebate Invoices	23
Veterans Health Care Act of 1992 (VHCA)	06
Virus Transmission Via Diskette	16, 18
Vitamins	30
Y2K	32, 33, 34